# Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma

> **NCT06562673** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai 6th People's Hospital** · enrollment: 10 (actual)

## Conditions studied

- Osteosarcoma
- Bone Cancer

## Interventions

- **DRUG:** intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)

## Key facts

- **NCT ID:** NCT06562673
- **Lead sponsor:** Shanghai 6th People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-03
- **Primary completion:** 2025-04-17
- **Final completion:** 2025-07-20
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06562673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06562673, "Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma". Retrieved via AI Analytics 2026-09-19 from https://api.ai-analytics.org/clinical/NCT06562673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*